Jasper Therapeutics falls about 50% after early-stage data for skin disease drug

Jasper Therapeutics

08/01/2025 14:34

** Drug developer Jasper Therapeutics' shares  JSPR.O  fall
~50% to $8.65 
    ** JSPR says its skin disease drug, briquilimab, met the
main goal in the early-stage trial for treating chronic
spontaneous urticaria (CSU)
    ** CSU is a skin condition where red, itchy bumps come and
go without a clear reason
    ** Brokerage William Blair says patients treated with the
180 milligram dose every 8 weeks showed a weaker reduction in
disease activity compared with other dose levels
    ** Brokerage says adverse events are not broken out by dose
level, making it difficult to assess the safety profile of
specific regimens
    ** Brokerage says 240 mg and 120 mg doses show strong
initial efficacy but lose effectiveness over time, raising
concerns about durability and long-term disease control
    ** All 11 brokerages rate the stock "buy" or higher; their
median PT is $69 - LSEG
    ** JSPR gained 13.6% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))